Seres Therapeutics stock jumps after naming co-CEOs
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc stock price live, this page displays NASDAQ MCRB stock exchange data. View the MCRB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Seres Therapeutics Inc real time stock price chart below.
What Is the Seres Therapeutics Inc Stock Price Today?
The Seres Therapeutics Inc stock price today is 13.0900.
What Is the Stock Symbol for Seres Therapeutics Inc?
The stock symbol for Seres Therapeutics Inc is ""MCRB.""
What Stock Exchange Does Seres Therapeutics Inc Trade On?
Seres Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Seres Therapeutics Inc a Good Stock to Buy?
Determining whether Seres Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MCRB quote. (ISIN: US81750R2013)
What Is the Seres Therapeutics Inc Stock Price Today?
The Seres Therapeutics Inc stock price today is 13.0900.
What Is the Stock Symbol for Seres Therapeutics Inc?
The stock symbol for Seres Therapeutics Inc is ""MCRB.""
What Stock Exchange Does Seres Therapeutics Inc Trade On?
Seres Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Seres Therapeutics Inc a Good Stock to Buy?
Determining whether Seres Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MCRB quote. (ISIN: US81750R2013)
NASDAQ
Currency in USD
13.0900
+0.7000(+5.65%)
Closed·
After Hours
12.8300-0.2600(-1.99%)
·
Fair Value
An estimate of a Seres Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.5000
13.2000
52 wk Range
6.5300
29.4000
MCRB Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected in 12 days
More Info
Fair Value
An estimate of a Seres Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.500013.2000
52 wk Range
6.530029.4000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MCRB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Seres Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
13.3333
Upside
+1.86%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Seres Therapeutics stock jumps after naming co-CEOs
- Investing.com
- Seres Therapeutics reports promising biomarker data
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Seres Therapeutics Inc Company Profile
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics Inc Earnings Call Summary for Q1/2025
- Net income surged to $32.7M in Q1 2025, reversing a $32.9M loss, driven by a $50M payment from Nestle
- Stock closed down 7.37% at $8.55 post-earnings, but rebounded 8.65% to $9.29 in premarket trading
- R&D and G&A expenses decreased year-over-year, indicating effective cost management efforts
- SER-155 advancing with FDA breakthrough therapy designation; Phase II study protocol submission imminent
- Company exploring partnerships to expand in inflammatory and immune disease markets
Last Updated: 07/05/2025, 14:24
Read Full TranscriptCompare MCRB to Peers and Sector
Metrics to compare | MCRB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMCRBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −5.1x | −0.5x | |
PEG Ratio | −0.01 | 0.02 | 0.00 | |
Price/Book | 2.3x | 3.5x | 2.6x | |
Price / LTM Sales | - | 218.6x | 3.2x | |
Upside (Analyst Target) | 13.0% | 132.6% | 42.7% | |
Fair Value Upside | Unlock | 6.3% | 5.8% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 13.3333
(+1.86% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
3.75 / 0.0651
Revenue / Forecast
-- / 20.00M
People Also Watch
FAQ
What Stock Exchange Does Seres Therapeutics Inc Trade On?
Seres Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Seres Therapeutics Inc?
The stock symbol for Seres Therapeutics Inc is "MCRB."
What Is the Seres Therapeutics Inc Market Cap?
As of today, Seres Therapeutics Inc market cap is 113.13M.
What Is Seres Therapeutics Inc's Earnings Per Share (TTM)?
The Seres Therapeutics Inc EPS (TTM) is -7.41.
When Is the Next Seres Therapeutics Inc Earnings Date?
Seres Therapeutics Inc will release its next earnings report on 04 Aug 2025.
From a Technical Analysis Perspective, Is MCRB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Seres Therapeutics Inc Stock Split?
Seres Therapeutics Inc has split 1 times.
How Many Employees Does Seres Therapeutics Inc Have?
Seres Therapeutics Inc has 103 employees.
What is the current trading status of Seres Therapeutics Inc (MCRB)?
As of 23 Jul 2025, Seres Therapeutics Inc (MCRB) is trading at a price of 13.09, with a previous close of 12.39. The stock has fluctuated within a day range of 12.50 to 13.20, while its 52-week range spans from 6.53 to 29.40.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.